Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: A meta-analysis

Gastroenterology

Volumn 129, Issue 4, 2005, Pages 1282-1293

  D'Amico, Gennaro ^a   Luca, Angelo ^b   Morabito, Alberto ^c   Miraglia, Roberto ^b   D'Amico, Mario ^a  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^b MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; DIURETIC AGENT; FUROSEMIDE; SPIRONOLACTONE;

ASCITES; BRAIN DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; COST BENEFIT ANALYSIS; EMBASE; HUMAN; INTERMETHOD COMPARISON; MEDLINE; META ANALYSIS; MORTALITY; PARACENTESIS; PORTOSYSTEMIC ANASTOMOSIS; PREDICTION; PRESSURE GRADIENT; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REGRESSION ANALYSIS; REVIEW; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STENT; SURVIVAL; SYSTEMATIC REVIEW;

EID: 26844549134     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2005.07.031     Document Type: Review

References (50)

1. V. Arroyo, J. Colmenero Ascites and hepatorenal syndrome in cirrhosis pathophysiological basis of therapy and current management J Hepatol 38 2003 S69 S89
2. J. Bosch, J.C. Garcia-Pagan Complications of cirrhosis. I. Portal hypertension J Hepatol 32 2000 141 146
3. P. Gines, M. Guevara, V. Arroyo, J. Rodes Hepatorenal syndrome Lancet 362 2003 1819 1827
4. S. Moller, H. Henriksen Review article pathogenesis and pathophysiology of hepatorenal syndrome - is there a scope for prevention? Aliment Pharmacol Ther 20 Suppl 3 2004 31 41
5. B.A. Runyon Refractory ascites Semin Liver Dis 13 1993 343 351
6. M.W. Russo, A. Sood, I.M. Jacobson, S.R. Brown Jr Transjugular intrahepatic portosystemic shunt for refractory ascites an analysis of the literature on efficacy, morbidity and mortality Am J Gastroenterol 98 2003 2521 2527
7. A. Ochs, M. Rossle, K. Haag, K.H. Hauenstein, P. Deibert, V. Siegerstetter, M. Huonker, M. Langer, H.E. Blum The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites N Engl J Med 332 1995 1192 1197
8. J. Quiroga, B. Sangro, M. Nuñez, I. Bilbao, J. Longo, L. Garcia-Villarreal, J.M. Zozaya Transjugular intrahepatic portosystemic shunt in the treatment of refractory ascites effect on clinical, renal, humoral, and hemodynamic parameters Hepatology 21 1995 986 994
9. E.H. Forrest, A.J. Stanley, D.N. Redhead, A.J. McGilchrist, P.C. Hayes Clinical response after transjugular intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis Aliment Pharmacol Ther 10 1996 801 806
10. D. Lebrec, N. Giuily, A. Hadengue, V. Vilgrain, R. Moreau, T. Poynard, A. Gadano Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial J Hepatol 25 1996 135 144
11. M. Rossle, A. Ochs, V. Gulberg, V. Siegerstetter, J. Holl, P. Deibert, M. Olschewski A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites N Engl J Med 342 2000 1701 1707
12. P. Gines, J. Uriz, B. Calahorra, G. Garcia-Tsao, P.S. Kamath, L.R. Del Arbol, R. Planas Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis Gastroenterology 123 2002 1839 1847
13. A.J. Sanyal, C. Genning, K.R. Reddy, F. Wong, K.V. Kowdley, K. Benner, T. McCashland The North American Study for the Treatment of Refractory Ascites Gastroenterology 124 2003 634 641
14. F. Salerno, M. Merli, O. Riggio, M. Cazzaniga, V. Valeriano, M. Pozzi, A. Nicolini, F. Salvatori GIST Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites Hepatology 40 2004 629 635
15. R.N. Pugh, I.M. Murray-Lyon, J.L. Dawson, M.C. Pietrni, R. Williams Transection of the esophagus for bleeding oesophageal varices Br J Surg 60 1973 646 649
16. S. Saab, J.M. Nieto, D. Ly, B.A. Runyon TIPS versus paracentesis for cirrhotic patients with refractory ascites Cochrane Database Syst Rev 3 2004 CD004889
17. H.O. Conn, M.M. Liebertal The hepatic coma syndromes and lactulose 1979 Williams & Wilkins Baltimore 46-84
18. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, J.M. Reynolds, D.J. Gavaghan, D.M. McQuay Assessing the quality of reports of randomized clinical trials is blinding necessary? Control Clin Trials 17 1996 1 12
19. D. Moher, B. Pham, A. Jones, D.J. Cook, A.R. Jadad, M. Moher Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352 1998 609 613
20. P. Juni, D.G. Altman, M. Egger Assessing the quality of controlled clinical trials BMJ 323 2001 42 46
21. L.L. Kjaergard, J. Villumsen, C. Gluud Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses Ann Intern Med 135 2001 982 989
22. K.F. Schulz, D.A. Grimes Generation of allocation sequences in randomised trials chance not choice Lancet 359 2002 515 519
23. K.F. Schulz, D.A. Grimes Allocation concealment in randomised trials defending against deciphering Lancet 359 2002 614 618
24. K.F. Schultz, A.D. Grimes Blinding in randomised trials Lancet 359 2002 696 700
25. R. Der Simonian, N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
26. A. Laupacis, D.L. Sackett, A.S. Roberts An assessment of clinically useful measures of the consequences of treatment N Engl J Med 318 1988 1728 1733
27. D.G. Altman Confidence intervals for the number needed to treat BMJ 317 1998 1309 1312
28. D. Petitti Approaches to heterogeneity in meta-analysis Stat Med 20 2001 3625 3633
29. S.G. Thompson, J.P.T. Higgins How should meta-regression analyses be undertaken and interpreted Stat Med 21 2002 1559 1573
30. S.G. Thompson, S.G. Sharp Explaining heterogeneity in meta-analysis a comparison of methods Stat Med 18 1999 2693 2708
31. C.B. Begg, M. Mazumadar Operating characteristics of a rank correlation test for publication bias Biometrics 50 1994 1088 1098
32. M. Egger, D.G. Smith, M. Schneider, C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
33. M. Malinchoc, P. Kamath, F.G. Gordon, C.J. Peine, J. Rank, C.G.P. Ter Borg A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts Hepatology 31 2000 864 871
34. A.L. Gerbes, V. Gulberg Benefit of TIPS for patients with refractory or recidivant ascites serum bilirubin may make the difference Hepatology 41 2005 217
35. K.D. Rajan, Z.J. Haskal, T.W.I. Clark Serum bilirubin and early mortality after transjugular intrahepatic portosystemic shunts results of a multivariate analysis J Vasc Interv Radiol 13 2002 156 161
36. A.K. Brensing, P. Raab, J. Textor, J. Gorich, P. Schiedermaier, H. Strunk, D. Paar Prospective evaluation of a clinical score for 60-day mortality after transjugular intrahepatic portosystemic stent-shunt Bonn TIPS early mortality analysis Eur J Gastroenterol Hepatol 14 2002 723 731
37. M. Rossle Discussion on the North American study for the treatment of refractory ascites Gastroenterology 126 2004 1214 1215
38. G. Garcia-Tsao Treatment of refractory ascites TIPS or TAPS Hepatology 33 2001 477 479
39. A.K. Burroughs, M. Vangeli Transjugular intrahepatic portosystemic shunt versus endoscopic therapy. Randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis Scand J Gastroenterol 37 2002 249 252
40. A.J. Sanyal, A.M. Freedman, M.L. Shiffman, P.P. Purdum III, V.A. Luketic, A.K. Cheatham Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt results of a prospective controlled study Hepatology 20 1994 46 55
41. K.A. Somberg, J.L. Riegler, M. Doherty Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts incidence and risk factors Am J Gastroenterol 4 1995 549 555
42. J. Cabrera, M. Maynar, R. Granados Tansjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage Gastroenterology 110 1996 832 839
43. M. Rössle, P. Deibert, K. Haag Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding Lancet 249 1997 1043 1049
44. P. Sauer, L. Theilmann, W. Stremmel, C. Benz, G.M. Richter, A. Stiehl Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for rebleeding Gastroenterology 113 1997 1623 1631
45. W. Nolte, J. Wiltfang, C. Schindler, H. Munke, K. Unterberg, U. Zumhasch, H.R. Figulla Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis clinical, laboratory, psychometric and electroencephalographic investigations Hepatology 28 1998 1215 1225
46. Z. Hassoun, M. Deschenes, M. Lafortune, M.P. Dufresne, P. Perrault, L. Lepanto, D. Gianfelice Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post-TIPS chronic hepatic encephalopathy Am J Gastroenterol 96 2001 1205 1209
47. C. Bureau, J.C. Garcia-Pagan, P. Otal, G. Pomier-Layrargues, V. Chabbert, C. Cortez, P. Perreault Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS results of a randomized study Gastroenterology 126 2004 469 475
48. P. Ginès, V. Arroyo, B. Vargas, R. Planas, F. Casafont, J. Panés, M. Hoyos Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites N Engl J Med 325 1991 829 835
49. V. Arroyo, P. Ginès, A.L. Gerbes, J.F. Dudley, P. Gentilini, G. Laffi, T.B. Reynolds Definitions and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis Hepatology 23 1996 164 176
50. H.O. Conn, C.M. Leevy, Z.R. Vlahcevic, J.B. Rodgers, W.C. Maddrey, L. Seef, L.L. Levy Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy Gastroenterology 72 1977 573 583